A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 May 2018
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Docetaxel
- Indications Head and neck cancer
- Focus Therapeutic Use
- 13 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Jan 2019.
- 13 Mar 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 20 Oct 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.